The third revision of the ICH S5 guidance for the Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals has recently been issued, and will soon be adopted by global regulatory authorities.
This webinar analyses its key takeaways and how the revisions may impact your drug development program. Join us to learn about:
- Changes to existing revisions
- New requirements, including inclusions for in vivo studies
- Implications for vaccines and biopharmaceuticals
- Options to defer studies
Alan Hoberman, PhD, DABT, Fellow ATS
Executive Director, Global Developmental, Reproductive, and Juvenile Toxicology
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.